Colorectal Cancer – Clinical impact of new data presented at ASCO 2014

MDoutlook has released its first of three OncoPoll™ report from ASCO 2014, describing the significant clinical impact of new data presented in Colorectal Cancer (CRC).

Our most recent latest research uncovers that:

  • Colorectal cancer is the main type of gastrointestinal cancers seen in clinical practices, making up approximately 85% of GI cancer patient flow 
  • FOLFOX + bevacizumab is and will remain the most common 1st line treatment approach for KRAS WildType metastatic colorectal cancer 
  • Adjuvant chemotherapy is seen as an important therapeutic approach for stage II and III rectal cancers

Request your complimentary copy of the 2014 ASCO OncoPoll – Colorectal Cancer report here. You will receive an email with the download link.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with all our colleagues.

MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Contact us to discuss how MDoutlook can answer your disease intelligence needs.